Autoimmune Diseases Stocks
Biopharmaceutical firms in this sector focus on modulating the immune system to treat chronic inflammatory conditions where the body attacks its own tissues. The revenue model relies on high-value biologic patents and long-term treatment cycles, targeting large patient populations across indications like rheumatoid arthritis, lupus, and dermatological disorders.
As of Oct 23, 2026, Autoimmune Diseases has 100 US-listed companies worth $2.7T combined. The median member moved +2.4% over the past week; VRDN led among the 25 largest at +17.6% and KNSA trailed at -2.4%.
Companies in Autoimmune Diseases
- LLY – Eli Lilly and Company, $1.1T
- ABBV – AbbVie Inc, $505B
- AZN – AstraZeneca PLC, $266B
- AMGN – Amgen Inc, $237B
- BMY – Bristol-Myers Squibb Company, $129B
- SNY – Sanofi ADR, $99.7B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- ARGX – argenx NV ADR, $54.9B
- ROIV – Roivant Sciences Ltd, $27.1B
- INCY – Incyte Corporation, $23.7B
- KYMR – Kymera Therapeutics Inc, $9.3B
- PTGX – Protagonist Therapeutics Inc, $9B
- TGTX – TG Therapeutics Inc, $8.1B
- KNSA – Kiniksa Pharmaceuticals Ltd, $6.3B
- IMVT – Immunovant Inc, $5.9B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- CRSP – Crispr Therapeutics AG, $4.8B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- NRIX – Nurix Therapeutics Inc, $2.9B
- VRDN – Viridian Therapeutics Inc, $2.5B
- HCM – HUTCHMED DRC, $2.5B
- CLDX – Celldex Therapeutics Inc, $2.3B
- VERA – Vera Therapeutics Inc, $2.2B
- AUPH – Aurinia Pharmaceuticals Inc, $2.2B
- ALVO – Alvotech, $1.9B
- XNCR – Xencor Inc, $1.9B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- ANAB – AnaptysBio Inc, $1.5B
- NKTR – Nektar Therapeutics, $1.2B
- TRAX – First Tracks Biotherapeutics, $1.2B
- VOR – Vor Biopharma Inc, $1.2B
- SVRA – Savara Inc, $1B
- CGEM – Cullinan Oncology LLC, $961M
- ALMS – Alumis Inc, $885M
- CRVS – Corvus Pharmaceuticals Inc, $876M
- ODTX – Odyssey Therapeutics, Inc. Common Stock, $871M
- JBIO – Jade Biosciences, Inc., $853M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- SANA – Sana Biotechnology Inc, $835M
- MLTX – MoonLake Immunotherapeutics, $813M
- IMMX – Immix Biopharma Inc, $803M
- AVTX – Avalo Therapeutics Inc, $728M
- ANNX – Annexon Inc, $726M
- CLYM – Climb Bio Inc, $592M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- STTK – Shattuck Labs Inc, $548M
- ALLO – Allogene Therapeutics Inc, $504M
- ACRS – Aclaris Therapeutics Inc, $483M
- AUTL – Autolus Therapeutics Ltd, $482M
- BLSM – BlossomHill Therapeutics, Inc. Common Stock, $458M
- ZURA – Zura Bio Limited Class A Ordinary Shares, $396M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- TRXB – TRex Bio, Inc. Common stock, $384M
- ENTA – Enanta Pharmaceuticals Inc, $352M
- ARTV – Artiva Biotherapeutics, Inc. Common Stock, $332M
- SABS – SAB Biotherapeutics Inc, $262M
- PALI – Palisade Bio Inc, $251M
- CABA – Cabaletta Bio Inc, $251M
- IPSC – Century Therapeutics Inc, $250M
- QTTB – Q32 Bio Inc, $232M
- FATE – Fate Therapeutics Inc, $231M
- IFRX – InflaRx N.V., $223M
- RNAC – Cartesian Therapeutics Inc., $202M
- XGN – Exagen Inc, $198M
- EVMN – Evommune, Inc., $188M
- YARW – Yarrow Bioscience Inc, $183M
- NKTX – Nkarta Inc, $161M
- UPB – Upstream Bio, Inc., $151M
- TLSA – Tiziana Life Sciences Ltd, $144M
- CUE – Cue Biopharma, $117M
- COYA – Coya Therapeutics, Inc. Common Stock, $116M
- ATRA – Atara Biotherapeutics Inc, $96M
- IMUX – Immunic Inc, $95.4M
- EQ – Equillium Inc, $83.7M
- CNTB – Connect Biopharma Holdings Ltd, $56.7M
- IMA – ImageneBio, Inc., $52.4M
- ACET – Adicet Bio Inc, $42.4M
- ALDX – Aldeyra The, $42.2M
- EDSA – Edesa Biotech Inc, $36.1M
- IMMP – Immutep Ltd ADR, $32.1M
- JSPR – Jasper Therapeutics Inc, $19M
- BMRA – Biomerica Inc, $8.6M
- FBLG – FibroBiologics, Inc. Common Stock, $8M
- APUS – Apimeds Pharmaceuticals US, Inc., $6.1M
- CANF – Can Fite Biopharma Ltd ADR, $5.9M
- TRIB – Trinity Biotech plc, $5.5M
- XTLB – XTL Biopharmaceuticals Ltd ADR, $4.6M
- GRI – GRI Bio Inc., $4.2M
- ERNA – Eterna Therapeutics Inc, $3.7M
- APVO – Aptevo Therapeutics Inc, $3.1M
- ADTX – Aditxt Inc. , $3M
- HCWB – HCW Biologics Inc, $2.8M
- VBIO – Valion Bio Inc, $2.2M
- SRNE – Sorrento Therape, $441,024
- CDT – Conduit Pharmaceuticals Inc., $209,159
- STAB – Statera Biopharma Inc, $7,141
- EVLO – Evelo Biosciences Inc, $3,796
- LIPO – Lipella Pharmaceuticals Inc. Common Stock, $2,310
- DICE – Dice Molecules Holdings LLC